Pfizer Targets Summer For COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works.

When Pfizer (NYSE: PFE) announced on April 9 that its five-point plan included a promising coronavirus treatment and a potential vaccine candidate in the works, shares soared to their highest point since the beginning of March. Pfizer stock has been on an upward trajectory ever since. The company is hoping to start phase 1 trials for its prospective coronavirus treatment by the fall. Pfizer is working on its vaccine candidate with German drugmaker BioNTech, with phase 1 trials expected to start before the month is out.

Pfizer's collaboration with BioNTech could significantly accelerate the vaccine development timeline. In fact, if the vaccine passes regulatory and clinical muster, the companies are looking at a vaccine launch date before the close of 2020. If you've been holding out on buying Pfizer shares, here's why now might be the time to invest in this stock.

Image source: Getty Images.

Source Fool.com